Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05413889 · ClinicalTrials.gov registry record · NA
Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model
A NA study of Unplanned Hospital Readmissions and Patients at High Risk of Unplanned Readmission, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT05413889: Completed NA study of Unplanned Hospital Readmissions and Patients at High Risk of Unplanned Readmission, sponsored by Wake Forest University Health Sciences.
NCT05413889 is a NA study of Unplanned Hospital Readmissions and Patients at High Risk of Unplanned Readmission that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 68 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05413889, a NA study of Unplanned Hospital Readmissions and Patients at High Risk of Unplanned Readmission, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is to assess the implementation of a computerized clinical decision support (cCDS) tool for identifying patients at high risk of unplanned readmission who could benefit from existing care programs aimed at reducing readmissions
Primary Outcome
Number of transitional and supportive care services (TSC) referrals by providers in the Intervention group
Conditions Studied
Interventions
- BEHAVIORAL Epic 30-day unplanned readmission risk score
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2023-08-17 |
| Phase | NA |
What the finished NCT05413889 record still lists
NCT05413889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Unplanned Hospital Readmissions appearing as the primary indexed condition, and to 1 intervention - of which Epic 30-day unplanned readmission risk score is the first listed.
NCT05413889 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05413889 about?
NCT05413889 is a clinical study titled "Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model". The objective is to assess the implementation of a computerized clinical decision support (cCDS) tool for identifying patients at high risk of unplanned readmission who could benefit from existing care programs aimed at reducing readmissions
What is the current status of trial NCT05413889?
This trial is currently completed. It is a NA study. The enrollment target is 68 participants. The study started on 2023-02-02. Estimated completion is 2023-08-17.
What conditions does trial NCT05413889 study?
This clinical trial studies the following conditions: Unplanned Hospital Readmissions, Patients at High Risk of Unplanned Readmission.
What interventions are being tested in trial NCT05413889?
The interventions under investigation include: Epic 30-day unplanned readmission risk score (BEHAVIORAL).
Who is sponsoring clinical trial NCT05413889?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05413889 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05413889's enrollment target sits among peer trials
68 1133rd of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI